Yale Image Finder

Search the actual image content of 1,538,051 (and growing!) Open Access images and figures from PubMed Central.


Advanced...

Related Figures


Figure 9 Effect of P. hexandrum sub-fraction (G-0...

Figure 10 Effect of P. hexandrum sub-fraction (G-0...

Figure 2 Plot of lung cancer risk per 10000 perso...

Figure 2 (a) CT of right para-aortic lymph node m...

Figure 5. Gamma irradiation induces accumulation o...

Figure 5 Different doses of P. hexandrum sub-frac...

Figure 5 Kaplan-Meier estimation of overall survi...

Figure 4 (a) CT of the left lung metastasis (arro...

Figure 3 Carcinoma (solid line) and sarcoma risk ...

Figure 4 Protein expression of TNF in the colon f...

Figure 1: Kaplan-Meier estimates for overall survival for the two radiotherapy fractionation schedules, 57 Gy in 19 fractions and 60 Gy in 20 fractions.

Image Text (High Precision): 57 Gy radiotherapy survival time

Other Images from "Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity":


Figure 1 Kaplan-Meier estimates for overall survi...

Figure 2 Kaplan-Meier estimates for biochemical p...

Figure 3 Late effects in normal tissues subjectiv...

Figure 4 Late effects in normal tissues subjectiv...

[Full Text] [PDF]

Abstract

Background. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial. Materials and Methods. 60 men with predominantly high-risk prostate cancer were treated. All patients received neoadjuvant hormone therapy, completing up to 6 months in total. Thirty patients were treated with 57 Gy in 19 fractions and 30 patients with 60 Gy in 20 fractions. Acute and 2-year toxicities were reported and patients followed longitudinally to assess 5 year outcomes and long-term toxicity. Toxicity was measured using RTOG criteria and LENT/SOMA questionnaire. Results. Median followup was 84 months. Five-year overall survival (OS) was 83% and biochemical progression-free survival (bPFS) was 50% for 57 Gy. Five-year OS was 75% and bPFS 58% for 60 Gy. At 7 years, toxicity by RTOG criteria was acceptable with no grade 3 or above toxicity. Compared with baseline, there was no significant change in urinary symptoms at 2 or 7 years. Bowel symptoms were stable between 2 and 7 years. All patients continued to have significant sexual dysfunction. Conclusion. In high-risk prostate cancer, dose-escalated hypofractionated radiotherapy using IMRT results in encouraging outcomes and acceptable late toxicity.


Search: Image Text (High Recall) Image Text (High Precision) Caption Abstract Title Full Text

All images and content copyright their respective owners. All else copyright ©2007-2008, Krauthammer Lab, Yale University.

Sign up for Yale Image Finder announcements:

Email: